title: Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study.
abstract: A population-based multicentre study for childhood acute lymphoblastic leukemia (ALL) was conducted in Hong Kong from 1993 to 1997. One hundred and forty-five newly diagnosed ALL patients were treated by the HKALL 93 protocol. Patients were stratified into three risk groups according to age, presenting white cell count, immunophenotyping and cytogenetic study. The patients received the same induction and early and late intensification at week 5 and week 20. Fifty-eight standard risk (SR) patients received regular intrathecal methotrexate as CNS preventive therapy, while 49 intermediate risk (IR) patients received high dose intravenous methotrexate and regular intrathecal methotrexate. Thirty-eight high risk (HR) patients were treated with prophylactic cranial irradiation and an additional intensification block at week 35. The induction remission rate was 97.2% with 2% induction death. Two patients died during first complete remission. Relapse occurred in 20.7, 42.9 and 42.1% of SR, IR and HR patients respectively. By multivariate logistic regression, age> or =10 years and white cell count> or =100 x 10(9)/l were the two significant variables accounting for mortality. The 5-year overall and event-free survival of the whole group was 81.3 and 62.6% respectively. According to risk groups, the event-free survival was 79, 49 and 61% for SR, IR and HR patients respectively, while the overall survival was 96, 73 and 68% for SR, IR and HR patients respectively. In conclusion, the treatment protocol had low treatment-related mortality but was associated with a rather high relapse rate, especially in IR patients. Salvage therapy achieved sustained second remission in some patients. More intensive treatment especially a late intensification is required to improve the outcome.
authors.affiliation: Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong. ckli@cuhk.edu.hk
authors.forename: C K
authors.initials: CK
authors.lastname: Li
authors.forename: K W
authors.initials: KW
authors.lastname: Chik
authors.forename: G C F
authors.initials: GC
authors.lastname: Chan
authors.forename: H L
authors.initials: HL
authors.lastname: Yuen
authors.forename: A C W
authors.initials: AC
authors.lastname: Lee
authors.forename: C Keung
authors.initials: CK
authors.lastname: Li
authors.forename: M M K
authors.initials: MM
authors.lastname: Shing
authors.forename: S Y
authors.initials: SY
authors.lastname: Ha
authors.forename: C W
authors.initials: CW
authors.lastname: Luk
authors.forename: S C
authors.initials: SC
authors.lastname: Ling
authors.forename: A Y K
authors.initials: AY
authors.lastname: Cheung
mesh_terms: D000293:Adolescent; D000367:Age Factors; D016543:Central Nervous System Neoplasms / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006723:Hong Kong; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D016015:Logistic Models; D008297:Male; D008727:Methotrexate / Q000494:pharmacology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D012044:Regression Analysis; D016879:Salvage Therapy; D013997:Time Factors
chemical_list: D008727:Methotrexate